Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 27, 2006

View Archived Issues

Clinical snapshots: cancer-related anemia, immune thrombocytopenic purpura

First trial of ProGenic pimecrolimus drug-eluting coronary stent opens enrollment

PsychoGenics and Lilly establish drug discovery and development agreement

Medivir and Presidio sign license agreements for alovudine and MIV-410

MediGene acquires E.U. rights to Oracea, establishes E.U. sales force

Indian approval for phase III evaluation of LLL-2011 for migraine prophylaxis

Regulatory pathway toward phase III and U.S. orphan drug designation for Ampydin (IR)

Rabirix rabies vaccine launched in India

Second phase III study for intravenous methylnaltrexone in POI

Outlicensing activities continue for CYT002-NicQb in nicotine addiction

MorphoSys and Pfizer expand therapeutic antibody collaboration

ADX-10059 begins proof-of-concept study in moderately severe dental anxiety

Bevirimat shows antiviral activity, but plasma concentrations lower than expected

Promising in vivo results with 17beta-HSD1 inhibitor from Sterix

Preliminary topline phase III results for PolyHeme

Androxal shows noninferiority to Androgel in phase III interim analysis

Targeting protein tyrosine phosphatase 1B shows promise for the treatment of heart failure

U.S. orphan drug designation for smallpox drug SIGA-246

Ista files IND for bepotastine eye drops for allergic conjunctivitis

Second approvable letter for Vyvanse

Approvable letter for Combigan

Exforge approved for hypertension

NDA submission for sevelamer carbonate for patients on dialysis

Japanese approval sought for Fosrenol in hyperphosphatemia

Recent patents disclose novel antiinfective agents

Recent Pfizer and Novartis patents impart new therapeutic agents for hypertension

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...